Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs

被引:10
作者
Cozma, Irina
Zhang, Lei
Uddin, James
Lane, Carol
Rees, Aled
Ludgate, Marian
机构
[1] Cardiff Univ, Sch Med, Dept Ophthalmol, Cardiff CF14 4XN, Wales
[2] Cardiff Univ, Sch Med, Ctr Endocrine & Diabet Sci, Cardiff, Wales
[3] Univ London, Moorfields Eye Hosp, London, England
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2007年 / 293卷 / 06期
基金
英国惠康基金;
关键词
somatostatin analogs; adipogenesis;
D O I
10.1152/ajpendo.00177.2007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cozma I, Zhang L, Uddin J, Lane C, Rees A, Ludgate M. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs. Am J Physiol Endocrinol Metab 293: E1630-E1635, 2007. First published September 11, 2007; doi: 10.1152/ajpendo.00177.2007. - Apart from evaluating orbital inflammation in Graves' ophthalmopathy ( GO), somatostatin (SST) analogs have been proposed as a therapy, but recent trials were disappointing. We aimed to measure somatostatin receptor ( SSTR) expression in orbital tissues ex vivo and determine whether the new broad-affinity analog SOM230 might be of therapeutic use. Orbital adipose/connective tissues from 29 GO patients and 10 normal individuals were analyzed. Transcripts were quantified using SYBR Green and a light cycler. In vitro models were used to investigate whether thyrotropin receptor activation ( as occurs via thyroid stimulating antibodies) or adipogenesis affected SSTR expression in primary preadipocytes and to compare the biological activity of octreotide and SOM230 in their modulation. The expression of SSTR1 was significantly higher in GO patients than normal controls ( P = 0.024). Although differences in the expression of SSTR2 were not significant, 39% of GO samples had levels above the 97th percentile of the controls. SSTR3, - 4, and - 5 were at or below the limit of detection (LOD). The lymphocyte contribution was minimal, since CD3 alpha transcripts were at the LOD. TSH receptor activation did not modulate SSTR expression. An in vitro model of adipogenesis indicated upregulation of SSTR1 and SSTR2 during differentiation. SOM230 produced significantly greater inhibition of orbital preadipocyte proliferation than octreotide. Ex vivo analysis of orbital tissues reveals upregulation of SSTR1 and - 2 in a group of GO patients. Adipogenesis, a process occurring in GO orbits, provides one possible explanation for some of the observed increase.
引用
收藏
页码:E1630 / E1635
页数:6
相关论文
共 25 条
[1]   Altered tear composition in smokers and patients with graves ophthalmopathy [J].
Baker, Glynn R. C. ;
Morton, Mike ;
Rajapaska, Rukshala S. ;
Bullock, Martyn ;
Gullu, Sevim ;
Mazzi, Barbara ;
Ludgate, Marian .
ARCHIVES OF OPHTHALMOLOGY, 2006, 124 (10) :1451-1456
[2]   Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial [J].
Chang, TC ;
Liao, SL .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2006, 29 (05) :413-422
[3]  
Crisp M, 2000, INVEST OPHTH VIS SCI, V41, P3249
[4]   Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy [J].
Dickinson, AJ ;
Vaidya, B ;
Miller, M ;
Coulthard, A ;
Perros, P ;
Baister, E ;
Andrews, CD ;
Hesse, L ;
Heverhagen, JT ;
Heufelder, AE ;
Kendall-Taylor, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12) :5910-5915
[5]   Biological activity of activating thyroid-stimulating hormone receptor mutants depends on the cellular context [J].
Fuhrer, D ;
Alkhafaji, LF ;
Starkey, K ;
Paschke, R ;
Wynford-Thomas, D ;
Eggo, M ;
Ludgate, M .
ENDOCRINOLOGY, 2003, 144 (09) :4018-4030
[6]  
Gaudillère A, 1999, EXP DERMATOL, V8, P267
[7]   Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy [J].
Gerding, MM ;
van der Zant, FM ;
van Royen, EA ;
Koornneef, L ;
Krenning, EP ;
Wiersinga, WM ;
Prummel, MF .
CLINICAL ENDOCRINOLOGY, 1999, 50 (03) :373-379
[8]   Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy [J].
Gerding, MN ;
van der Meer, JWC ;
Broenink, M ;
Bakker, O ;
Wiersinga, WM ;
Prummel, MF .
CLINICAL ENDOCRINOLOGY, 2000, 52 (03) :267-271
[9]   SOMATOSTATIN RECEPTOR SCINTIGRAPHY AND OCTREOTIDE TREATMENT IN PATIENTS WITH THYROID EYE DISEASE [J].
KRASSAS, GE ;
DUMAS, A ;
PONTIKIDES, N ;
KALTSAS, T .
CLINICAL ENDOCRINOLOGY, 1995, 42 (06) :571-580
[10]   Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy [J].
Kumar, S ;
Coenen, MJ ;
Scherer, PE ;
Bahn, RS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :930-935